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Huntington's disease is an inherited and incurable neurodegenerative disorder caused by an abnormal polyglutamine (polyQ) expansion in huntingtin (encoded by HTT ). PolyQ length determines disease onset and severity, with a longer expansion causing earlier onset. The mechanisms of mutant huntingtin-mediated neurotoxicity remain unclear; however, mitochondrial dysfunction is a key event in Huntington's disease pathogenesis 1, 2 . Here we tested whether mutant huntingtin impairs the mitochondrial fission-fusion balance and thereby causes neuronal injury. We show that mutant huntingtin triggers mitochondrial fragmentation in rat neurons and fibroblasts of individuals with Huntington's disease in vitro and in a mouse model of Huntington's disease in vivo before the presence of neurological deficits and huntingtin aggregates. Mutant huntingtin abnormally interacts with the mitochondrial fission GTPase dynamin-related protein-1 (DRP1) in mice and humans with Huntington's disease, which, in turn, stimulates its enzymatic activity. Mutant huntingtin-mediated mitochondrial fragmentation, defects in anterograde and retrograde mitochondrial transport and neuronal cell death are all rescued by reducing DRP1 GTPase activity with the dominant-negative DRP1 K38A mutant. Thus, DRP1 might represent a new therapeutic target to combat neurodegeneration in Huntington's disease.
Cycles of mitochondrial fission and fusion are necessary for neuronal function, and there is evidence that an imbalance in these opposing processes initiates neurodegeneration 3, 4 . Large GTPases of the dynamin family mediate mitochondrial fission and fusion, with DRP1 regulating mitochondrial fission and mitofusin regulating mitochondrial fusion 5, 6 . Mitochondrial defects and neuronal cell death caused by mutant huntingtin are events that could be explained by an altered mitochondrial fission-fusion equilibrium 1 .
To explore this possibility, we tested whether mutant huntingtin alters the mitochondrial morphology in rat cortical neurons or fibroblasts from humans with Huntington's disease. A polyQ expansion of 40 or more glutamines causes Huntington's disease. Neurons with exogenous expression of wild-type HTT ex1 -Q 17 (HTT exon 1 with 17 CAG repeats coding for a polyQ region with 17 glutamines) showed filamentous mitochondrial morphology, typical of healthy neurons (Fig. 1a) , with an average mitochondrial length of 3,200 nm. In contrast, neurons expressing mutant HTT ex1 -Q 46 showed round and elongated mitochondria ( Fig. 1a) . Neurons expressing mutant HTT ex1 -Q 97 revealed more profound mitochondrial fragmentation ( Fig. 1a) , with an average mitochondrial length of 800 nm. Further quantitative analysis indicated an increase in the percentage of neurons with fragmented mitochondria in neuronal populations expressing polyQs linked to disease (Q 46 and Q 97 ), with the Q 97 populations showing the most fragmentation ( Fig. 1b) . Mitochondrial numbers decreased (Supplementary Fig. 1 ) and autophagy increased ( Supplementary  Fig. 2 ) in neurons expressing mutant HTT. Using time-lapse imaging, we observed an increased ratio of fission over fission-plus-fusion events in neurons expressing mutant HTT, suggesting an imbalance in mitochondrial dynamics ( Supplementary Fig. 3 ). Finally, mitochondrial fragmentation correlated with neuronal cell death ( Fig. 1c) . A previous report showed that mutant HTT ex1 expression alone did not cause mitochondrial fragmentation in HeLa cells but only increased the vulnerability to hydrogen peroxide-induced fragmentation 7 .
Next, we used fibroblasts from individuals with Huntington's disease to investigate whether endogenous full-length mutant huntingtin can also alter mitochondrial morphology. Mitochondria in fibroblasts from an unaffected individual had the expected tubular morphology. In contrast, mitochondria from a person with Huntington's disease had shorter and rounder morphology, suggesting mitochondrial fragmentation ( Fig. 1d) . Quantitative analysis showed a higher percentage of fibroblasts with fragmented Mutant huntingtin binds the mitochondrial fission GTPase dynamin-related protein-1 and increases its enzymatic activity mitochondria for juvenile and adult-onset Huntington's disease ( Fig. 1e) . Thus, endogenous full-length mutant huntingtin causes mitochondrial fragmentation in fibroblasts from humans with Huntington's disease.
Mitochondrial fragmentation induced by nitric oxide (NO) arrests mitochondrial transport [8] [9] [10] . Furthermore, defects in transport of brain-derived neurotrophic factor vesicles and mitochondria have been linked to Huntington's disease 11, 12 . To test whether mutant huntingtin-induced mitochondrial fragmentation stalls mitochondrial transport, we tracked mitochondrial movement. Neurons expressing HTT ex1 -Q 17 had high anterograde and retrograde mitochondrial transport and velocity ( Fig. 1f,g and Supplementary Video 1). In contrast, neurons expressing HTT ex1 -Q 46 showed a decrease in both anterograde and retrograde mitochondrial transport and velocity ( Fig. 1f,g and Supplementary Video 2). The arrest in directional mitochondrial movement and velocity was even more pronounced in neurons expressing HTT ex1 -Q 97 (Fig. 1f,g and Supplementary Video 3). Quantitative analysis revealed a polyQ-length-dependent loss of bidirectional transport, mobility and velocity of mitochondria ( Fig. 1h) . Thus, mutant huntingtin-induced mitochondrial fragmentation correlates with an arrest in transport, which might negatively affect energy distribution at sites of high demand, such as synapses.
To investigate whether mitochondrial fragmentation initiated by the N-terminal huntingtin fragment and full-length endogenous huntingtin in vitro also occurs in vivo, we used mice that express the human full-length huntingtin with 18Q repeats (YAC18 control mice) or with 128Q repeats (YAC128 mutant huntingtin mice), driven by the endogenous promoter 13 . To test whether fragmentation occurs in YAC128 mice before disease onset and in the absence of huntingtin aggregates, we used electron microscopy. Mitochondria in the striatum of YAC18 control mice showed elongated morphology in neuronal processes ( Fig. 2a) . In YAC128 mice, however, we found fewer filamentous mitochondria and more small mitochondria in close proximity to each other ( Fig. 2a ). There was a significant increase (P < 0.05) in short mitochondria (<1,000 nm) and a decrease (P < 0.01) in long mitochondria (>1,000 nm) ( Fig. 2b) . These results suggest that mitochondrial fragmentation occurs in vivo in Huntington's disease mice before they start to show neurological deficits, neuronal cell death and huntingtin aggregate formation 14 .
To explore whether the mutant huntingtin-induced mitochondrial fragmentation produces ultrastructural changes in mitochondria, we performed electron microscope tomography. The three-dimensional structure of a typical mitochondrion from control mice has an elongated form and well-preserved outer and inner membrane structures, including tubular and lamellar cristae, commonly observed in striatal mitochondria (Fig. 2c,d and Supplementary Video 4) 15 . In contrast, the three-dimensional structure of the YAC128 mitochondrion shows the process of fragmentation into three parts ( Fig. 2e-g and Supplementary Video 5). The outer membrane shows constrictions between the three bodies ( Fig. 2e-g) . The segregation of cristae during the fragmentation process was complete between left and middle bodies but incomplete between middle and right bodies. YAC128 mitochondria had a higher density of cristae ( Fig. 2h) . Potential explanations for the cristae increase are that mutant huntingtin evokes cristae biogenesis or that cristae fragmentation occurs in addition to mitochondrial fragmentation. To distinguish between these two possibilities, we measured the ratio of total cristae membrane surface area to outer mitochondrial membrane surface area and the ratio of total cristae volume to mitochondrial volume ( Fig. 2i,j) . The YAC128 mitochondria had a mean cristae surface area ratio of 0.8 compared to 1.2 in controls ( Fig. 2i) . Furthermore, the YAC128 mitochondria had a mean cristae volume ratio of 0.11 compared to 0.16 in controls (Fig. 2j) . In sum, YAC128 mitochondria had almost 50% more cristae yet lower cristae surface area and volume ratios. These data suggest that mutant huntingtin does not cause cristae biogenesis but rather causes cristae fragmentation. These data agree with the inhibition of peroxisome proliferator-activated receptor γ coactivator 1-αmediated mitochondrial biogenesis by mutant huntingtin 16 . Thus, mitochondrial deficits in Huntington's disease may originate both from inappropriate and excessive mitochondrial fragmentation and impaired peroxisome proliferator-activated receptor γ coactivator 1-α-mediated de novo biogenesis 1 .
Mitochondrial fragmentation can be caused by stimulation of fission, inhibition of fusion or both. A potential mechanism by which mutant huntingtin may cause mitochondrial fragmentation could be via DRP1 S-nitrosylation 8, 9, [17] [18] [19] . However, we have found that DRP1 S-nitrosylation does not increase DRP1 GTPase activity 20 , leading us to conclude that DRP1 S-nitrosylation is not the basis for mutant huntingtin-mediated mitochondrial fragmentation. Alternatively, mutant huntingtin might trigger mitochondrial fragmentation by abnormal protein interactions 21, 22 . The normal function of huntingtin is that of a scaffold molecule regulating physiological processes via selective protein interactions. There is evidence that altered binding of mutant huntingtin with target proteins participates in Huntington's disease pathogenesis 22 . Mutant huntingtin binds mitochondria, where it can accumulate in large oligomers 12, 23, 24 . A similar subcellular distribution pattern has been documented for DRP1, which forms oligomers at mitochondrial division sites 25 . Whereas wild-type huntingtin ex1 -Q 25 showed largely cytoplasmic distribution, mutant huntingtin ex1 -Q 97 caused a significant increase (P < 0.01) in mitochondrial colocalization (Fig. 3a,b) . On the basis of these observations and supporting literature 2, 21, 23, 24, 26 , we speculated that mutant huntingtin might abnormally bind DRP1, thereby inappropriately shifting the mitochondrial fission-fusion balance.
To test whether mutant huntingtin interacts with DRP1, we first explored whether huntingtin and DRP1 colocalize on mitochondria in neurons. We found an overlap of mutant huntingtin and DRP1 fluorescent signals on mitochondria, suggesting that they may form a physical complex ( Fig. 3c and Supplementary Fig. 4) . To further investigate whether mutant huntingtin indeed binds Drp1, we isolated brain lysates from presymptomatic YAC18 and YAC128 mice and performed coimmunoprecipitations (Fig. 3d) . Although wild-type huntingtin also bound Drp1, we observed an increase in the mutant huntingtin-Drp1 interaction. (Fig. 3d) . The reverse immunoprecipitations confirmed our results (Fig. 3d) . Furthermore, the increased interaction was Drp1-specific and did not occur for mitofusin-2 (Mfn2) ( Supplementary Fig. 5 and Supplementary Fig. 6) .
To test whether the mutant huntingtin-Drp1 complex also exists in human Huntington's disease and occurs with endogenous huntingtin, we analyzed lymphoblasts and brain tissue of individuals with Huntington's disease. Similar to our results with Huntington's disease mice, mutant huntingtin precipitated with DRP1 more strongly than in nondiseased individuals (Fig. 3e,f) . In summary, the more prevalent mutant huntingtin-DRP1 interaction is of relevance to human Huntington's disease and occurs with endogenous fulllength huntingtin.
Because mutant huntingtin interacts with DRP1 in vivo, we tested whether mutant huntingtin binds DRP1 directly and with greater affinity than wild-type huntingtin in vitro. By immunoprecipitation experiments with purified proteins, we detected that wild-type huntingtin ex1 -Q 20 interacted either not at all or only weakly with DRP1. By contrast, mutant huntingtin was able to bind DRP1, suggesting that mutant huntingtin ex1 -Q 53 has a stronger affinity for DRP1 than wild-type huntingtin (Fig. 3g) .
Next, we wanted to test whether this interaction would alter DRP1's enzymatic activity and structure. Using liposomes that mimic the mitochondrial outer membrane (MOM) we observed a significant increase in the enzymatic activity (P < 0.05) and a significant decrease in the apparent K m (P < 0.01) with mutant huntingtin ( Fig. 3h and  Supplementary Table 1 ). This finding was not due to a contamination with another GTPase, because our DRP1 protein was pure (Supplementary Fig. 7) , and replacement of wild-type DRP1 with the enzymatically inactive DRP1 K38A mutant revealed no activity ( Fig. 3h and Supplementary Table 1 ). Using electron microscopy negative stain, we found that DRP1 forms ring-and spiral-like oligomers, similar to its yeast homolog ( Fig. 3i and Supplementary Fig. 8) 27, 28 . The DRP1 ring-like oligomer remained largely unaltered when we added wild-type huntingtin (data not shown). However, when we added mutant huntingtin, we observed an additional layer of density around the DRP1 ring-like oligomer (Fig. 3i) . Together, our in vitro results suggest that mutant huntingtin shows enhanced affinity to DRP1, alters its structure and stimulates its enzymatic activity. Although our data suggest a primary and direct activation of DRP1 by mutant huntingtin, we cannot exclude an inhibition of mitochondrial fusion.
Our data show that mutant huntingtin triggers mitochondrial fragmentation, which is linked to an arrest in mitochondrial transport and neuronal cell death. To test whether DRP1 and an altered fission-fusion equilibrium causes these events, we expressed the mutant DRP1 K38A either alone or in combination with the constitutively active mutant MFN2 RasG12V 29 ). Loss of DRP1 by shRNA expression altered neuronal differentiation (Supplementary Fig. 9) , yielding a phenotype similar to that in DRP1-null mice 30, 31 . We found a significant reduction in mitochondrial fragmentation (P < 0.01) ( Fig. 4a) and neuronal cell death (P < 0.01) (Fig. 4b) in neurons expressing mutant HTTwith either DRP1 K38A alone or in combination with MFN2 RasG12V. Last, transport, motility and velocity of mitochondria were all improved by re-establishing the mitochondrial fission and fusion balance ( Fig. 4c-e and Supplementary Fig. 10) . Previously, in a Caenorhabditis elegans model of Huntington's disease, DRP1 knockdown increased worm motility; however, the authors did not examine mitochondrial morphology or motility 7 . In sum, our data show that DRP1 has a function in mutant huntingtin-mediated neuronal injury and cell death. Our findings provide evidence that full-length mutant HTT expressed at physiological levels is sufficient to cause mitochondrial fragmentation in mice and individuals with Huntington's disease before cell death and aggregate formation. Mutant huntingtin-induced mitochondrial fragmentation impairs transport of mitochondria and reduces neuronal survival, as evidenced by the amelioration of these events upon prevention of mitochondrial fragmentation by DRP1 K38A alone or in combination with MFN2 RasG12V. Furthermore, mutant huntingtin abnormally interacts with DRP1 in Huntington's disease mice before disease onset. Last, the mutant huntingtin-DRP1 complex is likely to have a key pathophysiological role because it is present in individuals with Huntington's disease. Thus, DRP1 might constitute a new target for Huntington's disease therapy.
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